Suppr超能文献

基于负载淫羊藿苷的海藻酸钠-壳聚糖微球的结肠靶向口服给药系统治疗溃疡性结肠炎

Colon targeted oral drug delivery system based on alginate-chitosan microspheres loaded with icariin in the treatment of ulcerative colitis.

作者信息

Wang Qiang-Song, Wang Gui-Fang, Zhou Jie, Gao Li-Na, Cui Yuan-Lu

机构信息

Tianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300192, PR China.

Baokang Hospital, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, PR China.

出版信息

Int J Pharm. 2016 Dec 30;515(1-2):176-185. doi: 10.1016/j.ijpharm.2016.10.002. Epub 2016 Oct 3.

Abstract

In recent years, oral colon specific drug delivery system has been paid more attention in the treatment of inflammatory bowel disease (IBD). As the special pH condition in gastrointestinal tract, the challenge for treatment of IBD was that the colon drug delivery system should endure the low pH in stomach and release drugs quickly in high pH in colon. Icariin with the poor solubility and low bioavailability limited the treatment of many diseases in clinic. In this study, the protective mechanism of alginate-chitosan microspheres loaded with icariin were investigated with trinitrobenzene sulfonic acid (TNBS)/ethanol induced colonic mucosal injury in rats. The results of drug release showed that the icariin loaded into microspheres released only 10% in simulated gastric fluid and a high amount of 65.6% released in simulated colonic fluid. The fluorescence tracer indicated high retention of targeted microspheres more than 12h in colon. The microspheres loaded with icariin could not only reduce the colonic injury by decreasing the colon mucosa damage index in rats, but also reduce the inflammatory response by reducing the production and gene expression of inflammatory mediators and cytokines in colonic mucosa. All the results indicate that targeted microspheres loaded with icariin could exert the colon-protective effects through reducing the inflammatory response, which would be developed as a potential drug controlled release system for treatment of ulcerative colitis.

摘要

近年来,口服结肠特异性给药系统在炎症性肠病(IBD)的治疗中受到了更多关注。由于胃肠道特殊的pH条件,IBD治疗面临的挑战在于结肠给药系统要耐受胃内的低pH值,并在结肠的高pH值环境中快速释放药物。淫羊藿苷溶解度差、生物利用度低,限制了其在临床上对多种疾病的治疗。本研究采用三硝基苯磺酸(TNBS)/乙醇诱导大鼠结肠黏膜损伤,研究了载有淫羊藿苷的海藻酸钠-壳聚糖微球的保护机制。药物释放结果表明,载于微球中的淫羊藿苷在模拟胃液中仅释放10%,而在模拟结肠液中释放量高达65.6%。荧光示踪显示靶向微球在结肠中的高滞留时间超过12小时。载有淫羊藿苷的微球不仅可通过降低大鼠结肠黏膜损伤指数减轻结肠损伤,还可通过减少结肠黏膜中炎症介质和细胞因子的产生及基因表达减轻炎症反应。所有结果表明,载有淫羊藿苷的靶向微球可通过减轻炎症反应发挥结肠保护作用,有望开发成为治疗溃疡性结肠炎的潜在药物控释系统。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验